Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MITUL KANZARIA

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1639499023
CMS profile
210758
Location
SUNNYSIDE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,843.99

84 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,843.99 84

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MITUL KANZARIA

NPI 1639499023 · CMS profile ID 210758

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

SUNNYSIDE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639499023?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MITUL KANZARIA, NPI 1639499023, CMS profile ID 210758. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639499023?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MITUL KANZARIA, NPI 1639499023, CMS profile ID 210758. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639499023?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MITUL KANZARIA, NPI 1639499023, CMS profile ID 210758, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639499023?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

84 matching records · $1,843.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 84 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–84 of 84.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $9.5906/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810869 CMS
Abbott Laboratories $16.9006/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667332995 CMS
Cardiovascular Systems Inc. $15.8006/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702260247 CMS
Medtronic Vascular, Inc. $5.7305/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676982319 CMS
Boston Scientific Corporation $9.6905/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709062527 CMS
E.R. Squibb & Sons, L.L.C. $9.5405/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651315853 CMS
Novartis Pharmaceuticals Corporation $10.5505/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659665221 CMS
Janssen Pharmaceuticals, Inc $14.6905/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810862 CMS
Abbott Laboratories $24.9205/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667311045 CMS
Boston Scientific Corporation $1.7404/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709062523 CMS
E.R. Squibb & Sons, L.L.C. $14.9404/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651315851 CMS
Janssen Pharmaceuticals, Inc $5.7404/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810857 CMS
Janssen Pharmaceuticals, Inc $11.2604/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810853 CMS
Medtronic Vascular, Inc. $24.0204/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676954339 CMS
Boston Scientific Corporation $16.3104/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663159393 CMS
Medtronic Vascular, Inc. $65.7104/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676911731 CMS
Novartis Pharmaceuticals Corporation $12.9803/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659665215 CMS
Janssen Pharmaceuticals, Inc $13.2503/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810847 CMS
Novartis Pharmaceuticals Corporation $13.8203/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659665213 CMS
Janssen Pharmaceuticals, Inc $14.0702/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810841 CMS
Boston Scientific Corporation $3.9702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709062525 CMS
Novartis Pharmaceuticals Corporation $7.5902/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659665219 CMS
AstraZeneca Pharmaceuticals LP $14.8002/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685721221 CMS
Janssen Pharmaceuticals, Inc $13.4102/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810835 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.3902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625169859 CMS
AstraZeneca Pharmaceuticals LP $14.4902/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685294903 CMS
Janssen Pharmaceuticals, Inc $13.6801/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810826 CMS
Janssen Pharmaceuticals, Inc $6.8801/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810819 CMS
Boston Scientific Corporation $11.8801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663159379 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.0201/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700274047 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.8101/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625169855 CMS
CSL Behring $11.4001/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683874755 CMS
AstraZeneca Pharmaceuticals LP $177.5901/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685987157 CMS
Janssen Pharmaceuticals, Inc $14.8301/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,843.99 84
PY2020 $1,448.51 58
PY2021 $1,641.83 52
PY2022 $2,265.62 111
PY2023 $2,703.69 111
PY2024 $2,467.60 90
PY2025 $2,859.95 82

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,015.43 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Boehringer Ingelheim International GmbH $22.01 05/08/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779272
Recipient Boehringer Ingelheim International GmbH $123.97 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779246
Recipient Boehringer Ingelheim International GmbH $303.60 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779248
Recipient Boehringer Ingelheim International GmbH $20.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779254
Recipient Boehringer Ingelheim International GmbH $57.19 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779256
Recipient Boehringer Ingelheim International GmbH $40.45 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779258
Recipient Boehringer Ingelheim International GmbH $38.36 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779260
Recipient Boehringer Ingelheim International GmbH $124.99 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779262
Recipient Boehringer Ingelheim International GmbH $263.22 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779264
Recipient Boehringer Ingelheim International GmbH $60.06 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779266
Recipient Boehringer Ingelheim International GmbH $62.39 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779268
Recipient Boehringer Ingelheim International GmbH $20.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779270
Recipient Boehringer Ingelheim International GmbH $56.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779274
Recipient Boehringer Ingelheim International GmbH $130.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779276
Recipient Boehringer Ingelheim International GmbH $32.16 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779278
Recipient Boehringer Ingelheim International GmbH $61.32 05/06/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779250
Recipient Boehringer Ingelheim International GmbH $599.71 04/30/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779252